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IDH1mutation is the earliest genetic alteration in low-grade gliomas
(LGGs), but its role in tumor recurrence is unclear. Mutant IDH1 drives
overproduction of the oncometabolite D-2-hydroxyglutarate (2HG)
and a CpG island (CGI) hypermethylation phenotype (G-CIMP). To
investigate the role of mutant IDH1 at recurrence, we performed a
longitudinal analysis of 50 IDH1 mutant LGGs. We discovered six
cases with copy number alterations (CNAs) at the IDH1 locus at re-
currence. Deletion or amplification of IDH1 was followed by clonal
expansion and recurrence at a higher grade. Successful cultures de-
rived from IDH1 mutant, but not IDH1 wild type, gliomas systemat-
ically deleted IDH1 in vitro and in vivo, further suggestive of selection
against the heterozygous mutant state as tumors progress. Tumors
and cultures with IDH1 CNA had decreased 2HG, maintenance of
G-CIMP, and DNA methylation reprogramming outside CGI. Thus,
while IDH1 mutation initiates gliomagenesis, in some patients mu-
tant IDH1 and 2HG are not required for later clonal expansions.
IDH1 | DNA methylation | 2HG | glioma | copy number
Heterozygous mutations in IDH1 or IDH2 (collectively, IDH)are the earliest and most common genetic alteration in low-
grade gliomas (LGGs) and are frequently found in other cancers as
well, including acute myelogenous leukemia (AML) (1–4). Mutant
IDH produces high intracellular concentrations of the oncometa-
bolite D-2-hydroxyglutarate (2HG), which can activate some
α-ketoglutarate (αKG)-dependent enzymes and competitively in-
hibit others, including TET2 and histone demethylases (5–7). 2HG-
mediated inhibition of these epigenetic modifiers in IDH mutant
tumors is associated with increases in CpG island (CGI) DNA
methylation (in gliomas, the glioma CpG island methylator phe-
notype, or G-CIMP), changes in histone methylation patterns, and
changes in chromosome topology (7–9). Among all adult gliomas,
IDH mutant tumors are associated with the longest patient survival
(10, 11). IDHmutations and high levels of 2HG are associated with
a differentiation block, which can be released by treatment with
mutant IDH inhibitors; however, the effects of IDH inhibition may
depend on the disease, cell type, or tumor model (12–17).
The impact of IDH mutations on glioma progression remains
difficult to assess due to the difficulty of modeling these tumors.
While cell lines overexpressing the mutant enzyme have pro-
vided key insights, they do not accurately represent the hetero-
zygous mutant state of the disease. Considerable efforts have
been invested to establish brain tumor initiating cell (BTIC) lines
from IDH mutant gliomas and more closely recapitulate the bi-
ology of these tumors. However, patient-derived cells with endogenous
expression of mutant IDH are largely refractory in culture, al-
though xenografts from IDH mutant gliomas with tertiary mu-
tations have been established (18, 19).
In paired LGG samples, IDH mutations were shown to be
retained through tumor recurrence, in contrast to TP53, ATRX,
BRAF, and SMARCA4mutations that are occasionally “lost” (2, 3,
20). However, case reports suggest that the mutant or wild-type
IDH1 allele can be deleted during tumor recurrence and may be
selected against in vitro (21–25), raising the critical question of the
role of IDH mutations beyond tumor initiation. Here we used
longitudinally collected tumor samples to discover and characterize
the dynamic molecular, cellular, metabolic, and clinical features of
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initially IDH1 mutant LGG with and without subsequent copy
number alterations (CNAs) affecting IDH1. In addition, we de-
veloped cell culture and xenograft models that spontaneously and
systematically lost a copy of IDH1, and compared their metabolic
and epigenome changes with those seen in patient samples.
Results
Tumors with Altered Copy Number at IDH1. We performed exome
sequencing on a cohort of 50 paired initial LGGs and their
patient-matched recurrences (3, 26, 27) (SI Appendix, Table S1
and Dataset S1). All of the initial tumors had heterozygous
mutations in IDH1 or IDH2; however, in two recurrences (in
patients 14 and 169), the IDH1 mutant allele frequency (MAF)
dropped below the 10% minimum detection threshold (Fig. 1A
and SI Appendix, Table S2). Other mutations were retained (Fig.
1B and SI Appendix, Dataset S2), suggesting that recurrence in
these cases involved deletion of the mutant IDH1 allele.
To test for the suspected CNA, we used loss of heterozygosity
(LOH) analysis (28). For both recurrent tumors, the apparent
LOH suggested an allelic imbalance, which was confirmed as
single copy loss in total copy number (TCN) analysis (Fig. 1C and
SI Appendix, Fig. S1A). We next searched all tumors for LOH at
IDH1 or IDH2 and identified four additional cases (SI Appendix,
Fig. S1 and Table S2). To conclusively determine the copy number
at IDH1, we performed fluorescence in situ hybridization (FISH)
at the IDH1 locus (Fig. 1D and SI Appendix, Table S3). (The
exome data for one case was acquired from an outside institution
and was not analyzed further.) In patient 27, IDH1 CNAs were
present in both the initial and recurrent tumor, while the remaining
cases presented with IDH1 CNAs at recurrence. From these anal-
yses, we identified the genetic basis of potentially functional
changes in IDH1 TCN during malignant progression: deletion of
the mutant allele (patients 14 and 169), subclonal gain of the wild-
type allele (patient 68), subclonal gain of the mutant allele
(patient 17), and gain with additional subclonal amplification of
the mutant allele (patient 21) (SI Appendix, Table S2).
To investigate how well these single samples represented the
tumor overall, we analyzed new exome sequencing of spatially
distinct tumor tissue from patients 14, 68, and 169, along with
previously published data from patient 17 (3) (SI Appendix, Table
S2 and Dataset S1). These intratumoral analyses suggest that IDH1
CNAs were present throughout the recurrent tumors, yet were
undetectable in the initial tumor (Fig. 1A and SI Appendix, Fig. S1).
Thus, the CNAs were followed by substantial clonal expansion.
Copy Number Changes at IDH1 Impact mRNA and Protein Expression.
We next examined the impact of these genetic alterations on
IDH1 mRNA and protein levels. In each case with transcriptome
sequencing, the MAF from mRNA was very similar to the MAF
in DNA (Fig. 1A and SI Appendix, Table S2), suggesting that all
alleles were equally expressed. We then performed immunohis-
tochemistry (IHC) with an IDH1 R132H-specific antibody on all
available formalin-fixed, paraffin-embedded tumor blocks (SI
Appendix, Table S3). We found that the ploidy and chromosome
2 (chr2) CNAs manifested at the protein level, ranging from
absence of mutant protein following deletion of the mutant allele
to dramatically increased staining intensity following amplifica-
tion of the mutant allele (Fig. 1D and SI Appendix, Fig. S2).
Decreased 2HG and Increased Proliferation Following Amplification
or Deletion of Mutant IDH1. We next addressed the functional
consequences of IDH1 CNAs. IDH1 mutations are strictly het-
erozygous, maintaining a specific ratio of wild-type to mutant
enzymes for maximal production of 2HG (22, 29–32). IDH1
CNAs may shift this balance and lead to a paradoxical decrease
in the production of 2HG. We used NMR analysis of snap-frozen
tumor tissue to calculate the level of 2HG and then exome-
sequenced that tissue. In patient 14, 2HG was undetectable
following loss of the mutant allele (SI Appendix, Fig. S3A and
Table S2). Patient 21 had low levels of 2HG despite malignant
progression to high-grade glioblastoma (GBM), which typically
has elevated 2HG levels (33) (SI Appendix, Fig. S3 B and C and
Table S2). This is consistent with biochemical evidence indicating
that a relative abundance of mutant IDH1 decreases 2HG pro-
duction (22, 31, 32). In contrast, in patient 17 2HG levels fell in a
normal range for IDH mutant GBMs (34) (SI Appendix, Fig. S3 C
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Fig. 1. Deletion or amplification of mutant IDH1 during malignant pro-
gression. (A) Bar plot showing IDH1MAF in each exome. The RNA-seq MAF is
shown with a black triangle for samples with data. (B) Phylogenetic trees of
patients 14 and 169. Branch lengths are proportional to the number of
mutations detected. (C) LOH (Left) and TCN (Right) plots of chr2 for patient
169 initial A and recurrence 1 A. LOH is plotted as decrease in heterozygosity
from normal (0, no change; 1, complete loss of heterozygosity). (D) Repre-
sentative images for two distinct regions of patient 169 recurrence 1 (Left,
heterozygous IDH1 mutation; Right, deletion of mutant allele) and patient
21 recurrence 1 (Left, heterozygous IDH1 mutation; Right, chr2 gain and
amplification of IDH1). (Top) FISH for the centromere of chr2 (green) and
IDH1 (magenta). (Middle) IHC with an antibody specific to R132H mutant
IDH1. (Scale bar: 50 μm.) (Bottom) Ki-67 staining, with the percentage of
positive cells labeled. (Scale bar: 50 μm.) amp, amplification; del, single copy
deletion; mut, IDH1 mutant; N/A, not available; rec, recurrence.
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and D), potentially due to the subclonal nature of the CNA. In-
terestingly, the initial tumor from patient 169 showed little de-
tectable 2HG (SI Appendix, Fig. S3E), despite subsequent exome
sequencing of the tissue showing intact chr2, although with de-
creased IDH1 MAF (Fig. 1A and SI Appendix, Fig. S1F and Table
S2). This discrepancy may be due to a subclonal deletion, as IHC
for mutant IDH1 was negative in several regions of the initial tu-
mor. For all other tumors, exome-derived IDH1 MAFs on post-
NMR tissue were consistent with other tissue samples from the
same surgical resections (SI Appendix, Fig. S1 and Table S3). These
data further support in vivo clonal expansion of the cell that sus-
tained IDH1 CNA and had impaired 2HG production.
Mutant IDH1 and 2HG reduce BTIC proliferation in vitro (25,
31, 35). Indeed, recurrent tumors with IDH1 CNAs underwent
malignant progression to a higher grade (SI Appendix, Table S2).
Therefore, we asked whether the observed IDH1 CNAs and de-
crease in 2HG were associated with more proliferative tumor
clones. We counted Ki-67 positivity, a marker of actively cycling
cells, in tumors with regionally heterogeneous IDH1 R132H IHC
staining. In all three cases, the region with abnormal staining had a
higher Ki-67 index than the region with typical staining (P = 0.008,
paired t test) (Fig. 1D and SI Appendix, Table S4). Thus, clonal
IDH1 CNA and reduction of 2HG are associated with a more
proliferative state and outgrowth of a more aggressive tumor.
Systematic IDH1 Deletion in Vitro. A retrospective analysis showed
successful establishment of BTICs from 8% (4 of 49) of IDH
mutant gliomas, compared to 63% (62 of 99) from IDH wild-type
gliomas (P = 1 × 10−5, Fisher’s exact test) (SI Appendix, Table
S5), illustrating the refractory nature of IDH mutant cells to
in vitro culture. However, four BTIC lines were established from
grade III or IV IDH mutant tumors, three of which harbored
tertiary mutations that likely contributed to successful establish-
ment (19, 25, 36, 37) (SI Appendix, Tables S6 and S7 and Dataset
S3). However, these BTIC lines systematically lost either the
mutant or wild-type IDH1 allele (SI Appendix, Fig. S4A). Here we
confirmed previous findings (23, 25), using a higher resolution
copy number array, that each BTIC line derived from IDH1
mutant glioma has chr2 deletions encompassing IDH1 (Fig. 2A,
and SI Appendix, Fig. S4B and Table S6) despite globally similar
copy number profiles (SI Appendix, Fig. S4C). In contrast,
chr2 alterations were rare in a panel of 38 IDH wild-type tumors
and matched BTIC lines (Fig. 2 B and C and SI Appendix, Fig. S5).
Thus, selection of cells with chr2 deletions was exclusive to IDH
mutant gliomas, suggesting that this deletion confers a selective
growth advantage for IDH mutant gliomas in vitro (25).
We next asked whether IDH1 CNAs arose in vitro or if cells
with the deletion preexisted in the tumor. A low-frequency
mosaic deletion in BT92 tumor tissue suggested the latter sce-
nario (SI Appendix, Fig. S4B). CNA analysis of a separate piece
of BT92 tumor tissue identified a subclonal chr2 deletion
matching the deletion observed in the derived BTIC line (SI
Appendix, Fig. S6). Together with the CNA identified in our
cohort of paired primary gliomas, this suggests that cells with
IDH1 deletions exist in the tumor and are selected for in vitro.
IDH1 Deletion in Vivo.We further set out to determine whether the
selection for IDH1 CNA would be recapitulated in vivo. Primary
cells isolated from a secondary GBM (BT257; Fig. 2D) formed
spheres within the first week in culture (38) (Fig. 2E). Se-
quencing identified a rare IDH1 R132S mutation, which was
maintained in vitro (Fig. 2F). Although these cells remained vi-
able in culture for three months, they could not be successfully
expanded. Thus, all remaining viable cells were used for ortho-
topic xenografts. Within a year, all animals developed large
2HG-producing IDH1mutant tumors consistent with GBM (Fig.
2G and SI Appendix, Fig. S7 A–D). We maintained BT257
through serial xenografting, with survival ranging from three to
six months (Fig. 2H and SI Appendix, Fig. S7D). While hetero-
zygosity was maintained in the first xenograft, we observed a de-
crease in the height of the mutant peak in later xenografts (Fig.
2F). The BT257 tumor had no detectable alteration on chr2, with
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the exception of a focal amplification of MYCN (Fig. 2I), yet we
observed mosaic loss of chr2 being enriched from the primary
BTICs to X6-BTICs, correlating with the loss of the IDH1 mutant
allele (Fig. 2J and SI Appendix, Fig. S7E). IDH1 R132H and R132S
produce different amounts of 2HG, which could result in subtle
differences in selective pressure for IDH1 CNA events (35).
IDH1 Copy Number-Altered Tumors Retain G-CIMP. Given the wide-
spread DNA methylation changes associated with IDH mutations,
we investigated the DNA methylation dynamics of these tumors.
All tumors retained G-CIMP based on an eight-site definition (8)
and unsupervised hierarchical clustering with IDH mutant and
wild-type gliomas from TCGA (11, 39) (SI Appendix, Fig. S8).
Similarly, among 50 genes with G-CIMP–associated decreased
expression (8, 25), none significantly changed expression following
IDH1 CNA (SI Appendix, SI Materials and Methods). These anal-
yses, based on a subset of CpG sites, suggest a static methylome
during recurrence despite IDH1 CNA.
Recent analysis of G-CIMP–positive gliomas suggested that
subclassification into G-CIMP high and G-CIMP low can better
stratify by outcome (40). We wondered whether IDH1 CNA may
drive a shift from G-CIMP high to G-CIMP low with its asso-
ciated worse outcomes. We applied a random forest model built
on TCGA data to classify each sample from the five patients with
IDH1 CNAs and found that all samples from the three recur-
rences with clonal CNA were classified as G-CIMP low, while all
other samples were G-CIMP high (Fig. 3A and SI Appendix,
Table S8). This raises the possibility that G-CIMP–low tumors
have altered methylomes due to IDH1 CNA.
IDH1 Copy Number-Altered Tumors Exhibit Methylation Reprogramming
Outside of CGI. We used principal component analysis (PCA) to
provide a global view of DNA methylation patterns. Principal
components (PCs) 1 and 2 defined using TCGA gliomas separated
tumors by IDH mutation status; when we plotted the IDH1 CNA
cases on the same PCs, several of the recurrences appeared more
like the IDH wild-type TCGA tumors, while their initial IDH1
mutant counterparts resembled IDH mutant TCGA tumors (Fig.
3B). This dramatic shift within individual patients suggests that
despite retention of G-CIMP, these malignantly progressed tumors
have dynamically altered DNA methylation. Indeed, density plots,
average methylation per tumor, and average change in methylation
from the initial tumor to the IDH1 copy number-altered recurrence
indicate a decrease in methylation of much larger magnitude than
the decrease characteristic of malignant progression to GBM (26)
(Fig. 3 C and D and SI Appendix, Fig. S9A).
Because the persistence of G-CIMP indicated retained
hypermethylation within CGIs, we asked whether the hypo-
methylation occurred primarily outside of CGIs. Indeed, non-
CGI CpG sites clearly drove the hypomethylation (Fig. 3E).
While the pattern of hypomethylation was very strong in cases
with clonal CNA (patients 14, 21, and 169), it was moderate or
not detected in cases with subclonal CNA. Since the genomic
DNA for methylation analysis was derived from a larger tumor
area than the FISH analysis, subclonality might have muted the
signal of any aberrant hypomethylation.
If the epigenetic changes in tumors with clonal CNA are
mechanistically related to the decrease in 2HG as a consequence of
IDH1 CNA, then there should be a common set of altered CpG
sites. We calculated the change in methylation between initial and
recurrent tumors at each assayed CpG site and found that patients
14, 21, and 169 grouped together in unsupervised hierarchical
clustering and PCA (Fig. 4A and SI Appendix, Fig. S9B). Similarly,
the three highest pairwise correlations were among patients 14, 21,
and 169 (SI Appendix, Fig. S9C). Taken together, these analyses
demonstrate that similar CpG sites are altered following IDH1
CNA, suggesting a common effector.
To identify the CpGs that lose methylation following IDH1 CNA,
we compared the change in methylation between initial and recurrent
tumors with and without IDH1 CNA and identified 29,018 CpG sites
with significant hypomethylation specific to recurrence with IDH1
CNA (Fig. 4B). These CpG sites were underenriched in CGI and
overenriched in shores/shelves and non-CGI genomic spaces (P <
0.0001, permutation test) (Fig. 4C). While globally promoter CpG
sites were underenriched, there was a clear enrichment once CpG
sites in CGI were excluded (P < 0.0001, permutation test) (Fig.
4C). We performed gene ontology enrichment analysis on genes
with significant CpG sites in their promoters while excluding CpG
sites in CGI and found modest enrichments (Dataset S4).
Methylation Reprogramming Following IDH1 CNA in Vitro and in Vivo.
To further confirm that the identified DNA methylation changes
are related to IDH1 CNA, we profiled the BTICs and xenografts,
along with a second sample from each patient lacking the CNA:
tumor tissue, an earlier passage of BT142 before CNA, and a
primary culture derived from an earlier surgery that expanded
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Fig. 3. Loss of DNA methylation following deletion or amplification of mutant IDH1. (A) G-CIMP–high and G-CIMP–low scores for the initial-recurrent pairs
with IDH1 CNA. Samples are color-coded based on genetic status and shape reflects the G-CIMP–high/G-CIMP–low classification. “Pre-change” indicates the
initial tumor from patients with IDH1 CNA recurrent tumors. (B) PCA built on TCGA GBM and LGG initial tumors and applied to our cohort of 22 initial-
recurrent tumor pairs. (C) Boxplot of mean β values separated into normal brain (n = 53), IDH mutant LGG and patient-matched recurrences (n = 55) and the
IDH1 CNA patients (n = 28). (D and E) Mean change in methylation from initial to recurrence for each patient in the cohort, using all CpG sites (D) or divided
into those within CGIs, in CGI shores or shelves, or unassociated with a CGI (E). The number of CpG sites in each subset is provided in parentheses. amp,
amplification; del, single copy deletion; mut, IDH1 mutant; rec, recurrence.
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but did not establish (BT61, matching recurrent sample BT92).
All samples were G-CIMP–positive (SI Appendix, Fig. S8). Un-
supervised hierarchical clustering with the initial-recurrent tu-
mor pairs showed that samples with CNA, whether cell line,
xenograft, or primary tumor tissue, clustered together (Fig. 4D).
We then examined the 29,018 CpG sites that were associated
with CNA in the initial-recurrent tumor pairs. If the methylation
changes identified in the initial-recurrent tumor pairs are a sig-
nature of IDH1 CNA, then those same CpG sites should also
lose methylation in these models. We calculated the change in
methylation at each CpG site for each patient (SI Appendix,
Table S6). Examination of the methylation changes in the 29,018
CpG sites revealed decreased methylation in those CpG sites, with a
median methylation change of −0.07, compared with −0.0001 in the
background CpG sites (Fig. 4E). Thus, a common pattern of
methylation change is evident across in vitro BTICs, an in vivo xe-
nograft, and paired initial-recurrent patient tumors, suggesting that
IDH1 CNA truly leads to reprogramming of the DNA methylome.
Discussion
IDH mutations are typically retained upon recurrence, leading to
the initial hypothesis that these mutations play a role in tumor
recurrence. Our paired initial-recurrent gliomas show that gli-
oma cells can delete or amplify the mutant or wild-type allele,
altering the balanced ratio of wild-type and mutant IDH1 and
leading to disrupted or abolished production of 2HG. Cells with
IDH1 CNAs then clonally expand to occupy a substantial portion
of the recurrent tumor, suggesting a growth advantage. This is
confirmed by the in vitro and in vivo models described here, in
which deletion of either the mutant or wild-type IDH1 allele
occurs systematically in IDH mutant-derived BTICs, but not in
IDH wild-type–derived BTICs. This selection for CNA in vitro is
reminiscent of tumor-suppressor genes for which the frequency
of homozygous deletion or biallelic loss in primary cultures is el-
evated relative to tumor tissue (41, 42). In the case of IDH1 CNA,
however, the unifying feature is loss of the heterozygous mutant
state. In almost all of these cases, patients received temozolomide
(TMZ) before the recurrence with IDH1 CNA (SI Appendix, Table
S1), raising the possibility that TMZ treatment may contribute to
outgrowth of the CNA cells, perhaps by preferentially killing the
tumor cells that retain heterozygous IDH1 mutations (43).
Although derived from a relatively small number of cases, the
molecular, cellular, and metabolic data presented here, along with
genetics-focused case reports, suggest that mutant IDH1 is not strictly
required for recurrence (21–24). Model systems expressing mutant
IDH1 also suggest an abbreviated period during which inhibition of
mutant IDH1 affects cell proliferation (44). Recurrent tumors with
IDH1 CNA have some resemblance to the G-CIMP–low subtype
(40). Taken together, these data suggest that loss or inhibition of
mutant IDH may be associated with a more aggressive phenotype.
Small-molecule inhibition of mutant IDH1 in glioma cell lines
results in few DNA methylation changes (15, 17), yet our sam-
ples demonstrated massive hypomethylation and decreased 2HG
in cells with clonal IDH1 CNA. This may reflect the differences
of in vitro drug therapy relative to tumor evolution in patients or
differences among IDH1 inhibitors (45). A central question is
whether mutant IDH is a reasonable target for therapy. Early
clinical trial results suggest some efficacy in patients with IDH
mutant AML (4), but not yet in IDH mutant gliomas. IDH mu-
tant AML and gliomas have several key differences. While IDH
mutations in gliomas are prognostic of better outcomes, studies
in AML report conflicting impacts on survival (46). AML has a
higher frequency of IDH2 mutations and a more even distribu-
tion of different IDH1 mutations. This, combined with the dif-
ferent subcellular localization of IDH1 and IDH2, affects the
concentration of αKG, the NADP/NADPH ratio, and production
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of 2HG, and may account for different prognostic effects (32,
46). However, IDH mutations in AML, as in gliomas, are early
events that drive an altered epigenome and block cellular dif-
ferentiation (7). The efficacy of IDH inhibitors in AML may be
related to successful reversal of the differentiation block, a key
feature of other AML therapies (16, 47).
It is unlikely that an inhibitor of mutant IDH1 would have an
impact on tumor cell populations with IDH1 deletion, since the
target enzyme will not be present. Thus, we propose that longi-
tudinal monitoring of the IDH1 locus during treatment with
IDH1 inhibitors be incorporated into clinical trials to better
understand the role that such deletions may play in drug re-
sponse. In addition, mutations in IDH are associated with a wide
range of epigenetic, gene expression, and metabolic changes with
potential as therapeutic targets, possibly independent of whether
the tumor retains or loses mutant IDH1 (17, 48, 49).
Materials and Methods
Sample use was approved by the University of California San Francisco’s
Committee on Human Research, and this research was approved by the
University of California, San Francisco’s Institutional Review Board. Addi-
tional samples were collected following protocols approved by the Univer-
sity of Calgary’s Human Research Ethics Board. All patients provided
informed written consent. Animal studies were performed following in-
stitutional ethical guidelines and protocols approved by the University of
Calgary’s Animal Care Committee. BTIC lines were processed as described
previously (38). Genomic DNA was bisulfite-converted and processed on
Infinium HumanMethylation450 bead arrays according to the manufac-
turer’s protocol as described previously (26).
New exome sequencing, RNA sequencing, and DNA methylation array data
(accessionno. EGAS00001001854) andwholegenome sequencing (accessionno.
EGAS00001002618) have been deposited in the European Genome-Phenome
Archive database. EGA accession numbers for previously published data are
provided in SI Appendix, Dataset S1. Code is available on GitHub (https://github.
com/UCSF-Costello-Lab/IDH1_CNA).
Full details of all the protocols used in this study are provided in SI Ap-
pendix, Materials and Methods.
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